By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BG Medicine today announced a collaboration with Boston Scientific to study whether galectin-3 can be used to screen patients for cardiac-resynchronization therapy.

Data for their effort will come from the MADIT-CRT study, the world's largest randomized study of New York Heart Association Class I and II patients. The study involves more than 1,800 patients enrolled in 110 centers worldwide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.